---

---

publishing date : 2021 - 04 - 29    tags : Trial   

save search

---

Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe COVID-19 ARDS: Topline 60-Day Results From Randomized Controlled Trial
Published: 2021-04-29 (Crawled : 00:00) - globenewswire.com
MESO | $5.19 1.57% 1.54% 230K |

Health Technology

| -27.84% | O: 4.02% H: 19.71% C: 2.0%
covid results topline trial

---

Vinci Partners Real Estate Industrial Development Fund (VFDL) Announces First Capital Deployment
Published: 2021-04-29 (Crawled : 00:00) - globenewswire.com
VINP | News | $10.23 0.2% 0.2% 15K |

| -7.57% | O: -0.63% H: 2.45% C: 0.73%
ev trial

---

Yellow Corporation to Present at 2021 Virtual Wells Fargo Industrials Conference
Published: 2021-04-29 (Crawled : 19:00) - globenewswire.com
YELL | $1.1 -29.03% -44.19% 8.1M |

Transportation and Warehousing

| -88.47% | O: -1.36% H: 2.23% C: -2.55%
trial conference

---

Global Wireless Charging Market Report 2021: Growing Adoption of Wireless Charging in Industrial and Healthcare Applications for Continuous Power Supply
Published: 2021-04-29 (Crawled : 18:00) - prnewswire.com
QCOM | $157.65 -2.35% -2.4% 10M |

Electronic Technology

| 15.42% | O: 6.18% H: 0.2% C: -1.61%
growing charging trial application

---

Peer-Reviewed Results of Haemonetics' Improving Plasma Collection (IMPACT) Trial Published in the Journal TRANSFUSION
Published: 2021-04-29 (Crawled : 15:00) - biospace.com/
HAE | $81.24 -2.66% -1.65% 850K |

Health Technology

| 19.03% | O: 0.37% H: 1.15% C: -2.12%
results trial

---

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Published: 2021-04-29 (Crawled : 15:00) - biospace.com/
CARA | $0.6816 -1.22% -1.23% 350K |

Health Technology

| -97.44% | O: -43.48% H: 11.0% C: -3.47%
phase 2 results dermatitis topline trial atopic dermatitis

---

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting
Published: 2021-04-29 (Crawled : 14:15) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| -74.75% | O: 0.33% H: 0.77% C: -4.07%
phase 1 trial phase 3 phase 2

---

Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar
Published: 2021-04-29 (Crawled : 14:00) - prnewswire.com
CTXR | $0.7477 -7.18% -7.73% 1.7M |

Health Technology

| -61.93% | O: 1.07% H: 9.49% C: 5.98%
phase 3 trial

---

Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
Published: 2021-04-29 (Crawled : 14:00) - biospace.com/
AERI | $15.25 0.0% |

Health Technology

| -13.61% | O: -0.11% H: 2.16% C: -1.36%
dry eye disease treatment phase 2 eye eye disease phase 2b trial enroll

---

5G Industrial IoT Market by Component, Organization Size, Application, End-user and Region - Global Forecast to 2026
Published: 2021-04-29 (Crawled : 13:00) - prnewswire.com
KT | $12.2 0.25% 0.0% 340K |

Communications

| -5.35% | O: 0.47% H: 0.5% C: 0.46%
ERIC | News | $5.1 0.79% 0.78% 19M |

Electronic Technology

| -63.68% | O: 0.0% H: 0.25% C: -0.5%
5g iot trial application

---

AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting
Published: 2021-04-29 (Crawled : 12:00) - globenewswire.com
AGTC | $0.3936 1.23% 0.0% |

Health Technology

| -90.56% | O: 3.12% H: 1.86% C: 0.0%
ongoing clinical trials trial

---

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
Published: 2021-04-29 (Crawled : 08:00) - biospace.com/
AVIR | $3.7 0.0% 220K |

Health Technology

| -86.04% | O: 1.58% H: 0.44% C: -2.55%
covid treatment phase 3 trial at-527

---

WillScot Mobile Mini Holdings to Participate in the Oppenheimer Industrial Growth Conference
Published: 2021-04-29 (Crawled : 06:00) - globenewswire.com
WSC | $38.47 1.29% 1.27% 3M |

Finance

| 27.86% | O: 1.0% H: 0.0% C: -2.57%
mobile growth trial conference

---

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration
Published: 2021-04-29 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 302.28% | O: 0.28% H: 0.87% C: 0.63%
phase 2 trial macular

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---